- idUS
- Listar por autor
Listar por autor "Gogas, Helen"
Mostrando ítems 1-3 de 3
-
Artículo
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival
Mandala, Mario; Larkin, James R.; Ascierto, Paolo Antonio; Del Vecchio, Michele; Gogas, Helen; Cruz Merino, Luis de la; Weber, Jeffrey; Lobo, Maurice (BMJ Publishing Group, 2021-08-21)Background Several therapeutic options are now available in the adjuvant melanoma setting, mandating an understanding ...
-
Artículo
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria
Larkin, James; Weber, Jeffrey; Del Vecchio, Michele; Gogas, Helen; Arance, Ana M.; Dalle, Stephane; Cruz Merino, Luis de la; Mandalá, Mario (Elsevier Science Ltd, 2022)Abstract Purpose: Nivolumab was approved as adjuvant therapy for melanoma based on data from CheckMate 238, which enrolled ...
-
Artículo
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
Larkin, James; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance Fernandez, Ana M.; Dalle, Stéphane; Cruz Merino, Luis de la; Weber, Jeffrey (American Association Cancer Research, 2023)lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in ...